Discovery of novel ATAD2 bromodomain inhibitors that trigger apoptosis and autophagy in breast cells by structure-based virtual screening

References

• Ali I, Conrad RJ, Verdin E, Ott M. Lysine acetylation goes global: from epigenetics to metabolism and therapeutics. Chem Rev 2018;118:1216–52.
   PubMed Web of Science ®Google Scholar
• Feller C, Forne I, Imhof A, Becker PB. Global and specific responses of the histone acetylome to systematic perturbation. Mol Cell 2015;57:559–71.
   PubMed Web of Science ®Google Scholar
• Kaypee S, Sudarshan D, Shanmugam MK, et al. Aberrant lysine acetylation in tumorigenesis: implications in the development of therapeutics. Pharmacol Ther 2016;162:98–119.
   PubMed Web of Science ®Google Scholar
• Dhalluin C, Carlson JE, Zeng L, et al. Structure and ligand of a histone acetyltransferase bromodomain. Nature 1999;399:491–6.
   PubMed Web of Science ®Google Scholar
• Romero FA, Taylor AM, Crawford TD, et al. Disrupting acetyl-lysine recognition: progress in the development of bromodomain inhibitors. J Med Chem 2016;59:1271–98.
   PubMed Web of Science ®Google Scholar
• Cattaneo M, Morozumi Y, Perazza D, et al. Lessons from yeast on emerging roles of the atad2 protein family in gene regulation and genome organization. Mol Cells 2014;37:851–6.
   PubMed Web of Science ®Google Scholar
• Morozumi Y, Boussouar F, Tan M, et al. Atad2 is a generalist facilitator of chromatin dynamics in embryonic stem cells. J Mol Cell Biol 2016;8:349–62.
   PubMed Web of Science ®Google Scholar
• Fouret R, Laffaire J, Hofman P, et al. A comparative and integrative approach identifies atpase family, AAA domain containing 2 as a likely driver of cell proliferation in lung adenocarcinoma. Clin Cancer Res 2012;18:5606–16.
   PubMed Web of Science ®Google Scholar
• Hou M, Huang R, Song Y, et al. Atad2 overexpression is associated with progression and prognosis in colorectal cancer. Jpn J Clin Oncol 2016;46:222–7.
   PubMed Web of Science ®Google Scholar
• Zhang M, Zhang C, Du W, et al. Atad2 is overexpressed in gastric cancer and serves as an independent poor prognostic biomarker. Clin Transl Oncol 2016;18:776–81.
   PubMed Web of Science ®Google Scholar
• Caron C, Lestrat C, Marsal S, et al. Functional characterization of atad2 as a new cancer/testis factor and a predictor of poor prognosis in breast and lung cancers. Oncogene 2010;29:5171–81.
   PubMed Web of Science ®Google Scholar
• Zou JX, Duan Z, Wang J, et al. Kinesin family deregulation coordinated by bromodomain protein ANCCA and histone methyltransferase mll for breast cancer cell growth, survival, and tamoxifen resistance. Mol Cancer Res 2014;12:539–49.
   PubMed Web of Science ®Google Scholar
• Ji S, Su X, Zhang H, et al. Microrna-372 functions as a tumor suppressor in cell invasion, migration and epithelial-mesenchymal transition by targeting ATAD2 in renal cell carcinoma. Oncol Lett 2019;17:2400–8.
   PubMed Web of Science ®Google Scholar
• Duan Z, Andrews NP, Chen CZ, et al. Targeting bromodomain protein ancca/atad2 enhances the efficacy of DNA damaging chemotherapy agents and radiation. Oncol Rep 2020;43:318–27.
   PubMed Web of Science ®Google Scholar
• Revenko AS, Kalashnikova EV, Gemo AT, et al. Chromatin loading of e2f-mll complex by cancer-associated coregulator ANCCA via reading a specific histone mark. Mol Cell Biol 2010;30:5260–72.
   PubMed Web of Science ®Google Scholar
• Kalashnikova EV, Revenko AS, Gemo AT, et al. ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-MYB and ezh2. Cancer Res 2010;70:9402–12.
   PubMed Web of Science ®Google Scholar
• Zou JX, Revenko AS, Li LB, et al. ANCCA, an estrogen-regulated AAA + ATPase coactivator for ERalpha, is required for coregulator occupancy and chromatin modification. Proc Natl Acad Sci USA 2007;104:18067–72.
   PubMed Web of Science ®Google Scholar
• Lloyd JT, Glass KC. Biological function and histone recognition of family IV bromodomain-containing proteins. J Cell Physiol 2018;233:1877–86.
   PubMed Web of Science ®Google Scholar
• Harner MJ, Chauder BA, Phan J, Fesik SW. Fragment-based screening of the bromodomain of ATAD2. J Med Chem 2014;57:9687–92.
   PubMed Web of Science ®Google Scholar
• Demont EH, Chung CW, Furze RC, et al. Fragment-based discovery of low-micromolar ATAD2 bromodomain inhibitors. J Med Chem 2015;58:5649–73.
   PubMed Web of Science ®Google Scholar
• Bamborough P, Chung CW, Furze RC, et al. Structure-based optimization of naphthyridones into potent ATAD2 bromodomain inhibitors. J Med Chem 2015;58:6151–78.
   PubMed Web of Science ®Google Scholar
• Bamborough P, Chung CW, Demont EH, et al. A chemical probe for the ATAD2 bromodomain. Angew Chem Int Ed Engl 2016;55:11382–6.
   PubMed Web of Science ®Google Scholar
• Fernandez-Montalvan AE, Berger M, Kuropka B, et al. Isoform-selective ATAD2 chemical probe with novel chemical structure and unusual mode of action. ACS Chem Biol 2017;12:2730–6.
   PubMed Web of Science ®Google Scholar
• Bamborough P, Chung CW, Furze RC, et al. Aiming to miss a moving target: Bromo and extra terminal domain (bet) selectivity in constrained atad2 inhibitors. J Med Chem 2018;61:8321–36.
   PubMed Web of Science ®Google Scholar
• Bamborough P, Chung CW, Demont EH, et al. A qualified success: discovery of a new series of ATAD2 bromodomain inhibitors with a novel binding mode using high-throughput screening and hit qualification. J Med Chem 2019;62:7506–25.
   PubMed Web of Science ®Google Scholar
• Case DA, Cheatham TE, 3rd, Darden T, et al. The amber biomolecular simulation programs. J Comput Chem 2005;26:1668–88.
   PubMed Web of Science ®Google Scholar
• Romero FA, Murray J, Lai KW, et al. Gne-781, a highly advanced potent and selective bromodomain inhibitor of cyclic adenosine monophosphate response element binding protein, binding protein (CBP). J Med Chem 2017;60:9162–83.
   PubMed Web of Science ®Google Scholar
• Hussain M, Zhou Y, Song Y, et al. Atad2 in cancer: a pharmacologically challenging but tractable target. Expert Opin Ther Targets 2018;22:85–96.
   PubMed Web of Science ®Google Scholar